MICS Centrum Medyczne Warszawa
- Address
- ul. Wronia 53 lok. b10, 00-874 Warsaw, Poland
Immune System Diseases and Inflammatory Rheumatology
At MICS Centrum Medyczne Warszawa, clinical research in this area focuses on immune-mediated diseases such as active psoriatic arthritis, systemic lupus erythematosus, and Sjögren’s syndrome. These studies are designed to evaluate new treatments that may help reduce disease activity, improve symptoms, and support better long-term control of chronic autoimmune conditions.
- Testing whether new therapies can better control psoriatic arthritis symptoms and joint inflammation
- Evaluating treatment effectiveness in systemic lupus erythematosus to reduce overall disease activity
- Assessing options for Sjögren’s syndrome to improve systemic disease manifestations
These trials reflect a strong interest in advancing care for complex autoimmune disorders that affect the immune system and cause ongoing inflammation.
Skin and Connective Tissue Diseases
Research at this site also includes studies in skin and connective tissue diseases, especially cutaneous lupus and systemic sclerosis. The trials aim to improve treatment for patients with difficult-to-manage skin involvement, with a focus on reducing visible disease activity, easing sclerosis, and supporting better quality of life.
- Studying therapies for subacute cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus
- Evaluating new approaches for diffuse cutaneous systemic sclerosis and skin thickening
- Looking at whether emerging treatments can improve skin disease activity and related symptoms
These investigations are important for patients whose disease affects both the skin and broader connective tissue systems.
Immune System Phenomena and Systemic Autoimmune Activity
The clinical trial portfolio at the Warsaw site includes research into the underlying immune system processes that drive autoimmune disease activity. Rather than focusing only on symptoms, these studies aim to better understand and interrupt the inflammatory pathways involved in conditions such as lupus and systemic sclerosis.
- Exploring how new therapies may influence immune system signaling in autoimmune disease
- Assessing whether treatments can reduce systemic inflammation and disease flare-ups
- Supporting research into more targeted approaches for chronic immune-mediated disorders
This line of research may help improve future treatment strategies for patients with persistent and complex autoimmune conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Argenx1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MICS Centrum Medyczne Warszawa
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study | Horizon Therapeutics Ireland Designated Activity Company | Phase III | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Afimetoran Besilate Dihydrate | 1 | Unknown | 2021-11-25 | 2021-11-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.